Aflibercept: An update on recent milestones achieved

Neal Palejwala, Andreas (Andy) Lauer

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu - mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.

Original languageEnglish (US)
Pages (from-to)779-790
Number of pages12
JournalDrugs of Today
Volume50
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Vascular Endothelial Growth Factor A
Retinal Vein Occlusion
Macular Degeneration
Edema
Retinal Diseases
Retinal Vessels
Vascular Diseases
Visual Acuity
Protein Isoforms
Therapeutics
Clinical Trials
Pharmaceutical Preparations
aflibercept
Ranibizumab
Bevacizumab
pegaptanib
Placenta Growth Factor

Keywords

  • Aflibercept
  • Branch retinal vein occlusion
  • Diabetic macular edema
  • Eye
  • Macular edema
  • Neovascular wet age
  • Related macular degeneration
  • VEGF Trap

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Aflibercept : An update on recent milestones achieved. / Palejwala, Neal; Lauer, Andreas (Andy).

In: Drugs of Today, Vol. 50, No. 12, 01.12.2014, p. 779-790.

Research output: Contribution to journalArticle

Palejwala, Neal ; Lauer, Andreas (Andy). / Aflibercept : An update on recent milestones achieved. In: Drugs of Today. 2014 ; Vol. 50, No. 12. pp. 779-790.
@article{bf011b4ef1124b6cb09537b9a38798f7,
title = "Aflibercept: An update on recent milestones achieved",
abstract = "In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu - mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.",
keywords = "Aflibercept, Branch retinal vein occlusion, Diabetic macular edema, Eye, Macular edema, Neovascular wet age, Related macular degeneration, VEGF Trap",
author = "Neal Palejwala and Lauer, {Andreas (Andy)}",
year = "2014",
month = "12",
day = "1",
doi = "10.1358/dot.2014.50.12.2245587",
language = "English (US)",
volume = "50",
pages = "779--790",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "12",

}

TY - JOUR

T1 - Aflibercept

T2 - An update on recent milestones achieved

AU - Palejwala, Neal

AU - Lauer, Andreas (Andy)

PY - 2014/12/1

Y1 - 2014/12/1

N2 - In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu - mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.

AB - In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu - mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.

KW - Aflibercept

KW - Branch retinal vein occlusion

KW - Diabetic macular edema

KW - Eye

KW - Macular edema

KW - Neovascular wet age

KW - Related macular degeneration

KW - VEGF Trap

UR - http://www.scopus.com/inward/record.url?scp=84920028331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920028331&partnerID=8YFLogxK

U2 - 10.1358/dot.2014.50.12.2245587

DO - 10.1358/dot.2014.50.12.2245587

M3 - Article

C2 - 25588083

AN - SCOPUS:84920028331

VL - 50

SP - 779

EP - 790

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 12

ER -